Topics in this section

Hepatitis and HIV: latest news

Hepatitis and HIV resources

Hepatitis and HIV features

Hepatitis and HIV in your own words

Hepatitis and HIV news from aidsmap

More news

Hepatitis and HIV news selected from other sources

  • In patients co-infected with HIV, combination antiretroviral therapy helps treat HCV

    Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published in Science Translational Medicine.

    25 July 2014 | HIV / AIDS News From Medical News Today
  • US: Studies look at hepatitis C care cascade and healthcare utilization

    Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE.

    08 July 2014 | HIVandHepatitis.com
  • Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen

    Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor.

    08 July 2014 | Bristol-Myers Squibb press release
  • UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

    The US Food and Drug Administration (FDA) has granted priority review for AbbVie’s experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug’s application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. AbbVie’s new regimen consists of an antiviral called ritonavir and a protease inhibitor called ABT-450, combined with an NS5A inhibitor called ombitasvir and the polymerase inhibitor dasabuvir. When taken together, these mechanisms are powerful enough to stop HCV. [Article source: http://www.techtimes.com]

    19 June 2014 | CDC
  • NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

    In draft recommendations published today healthcare guidance body NICE is asking Gilead Sciences for more information on its product sofosbuvir (Sovaldi), for the treatment of chronic hepatitis C. “The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients. However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer.”

    16 June 2014 | NICE press release
  • FDA lifts hold on Achillion's hepatitis C drug, shares jump

    Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, sovaprevir, lifting a clinical hold that was imposed nearly a year ago. The company's shares soared as much 56 percent to $6.65 on the Nasdaq on Tuesday. Merck & Co's planned acquisition of Idenix Pharmaceuticals, announced on Monday, leaves Achillion as the only unencumbered company developing drugs that block a protein required by the hepatitis C virus to replicate.

    11 June 2014 | Reuters
  • England: New study reveals the costs of low uptake of hepatitis C treatment

    While there would be a financial cost to rapidly increasing treatment rates, the increase is not as great as you might think because the costs of managing undiagnosed and untreated hepatitis C are so high. Currently, we are paying a very high price in terms of lives lost and burden placed on future health care resources.

    10 June 2014 | Public Health England (press release)
  • OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

    Simeprevir provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe

    16 May 2014 | Reuters
  • To curb hepatitis C, test and treat inmates

    The nation's oversized prison population provides an opportunity to battle the US hepatitis C epidemic because inmates have a high prevalence of infection and are readily reachable for testing and treatment, argue authors of a new article in the New England Journal of Medicine. One in six inmates is infected and one in three infected Americans ends up locked up for at least a little time in their lives.

    15 May 2014 | Eurekalert Inf Dis
  • Anti-HBV antiretrovirals may help ward off HBV infection in MSM

    Three antiretrovirals that also help control hepatitis B virus (HBV) infection—tenofovir, emtricitabine, and lamivudine—may also prevent HBV infection, according to results of a retrospective analysis involving men who have sex with men (MSM) in the Netherlands.

    24 April 2014 | International AIDS Society
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also